Skip to Content

Generic Invokana Availability

Invokana is a brand name of canagliflozin, approved by the FDA in the following formulation(s):

INVOKANA (canagliflozin - tablet;oral)

  • Manufacturer: JANSSEN PHARMS
    Approval date: March 29, 2013
    Strength(s): 100MG, 300MG [RLD]

Has a generic version of Invokana been approved?

No. There is currently no therapeutically equivalent version of Invokana available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invokana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
    Patent 7,943,582
    Issued: May 17, 2011
    Inventor(s): Nomura; Sumihiro & Kawanishi; Eiji
    Assignee(s): Mitsubishi Tanabe Pharma Corporation
    A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.
    Patent expiration dates:
    • February 26, 2029
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Glucopyranoside compound
    Patent 7,943,788
    Issued: May 17, 2011
    Inventor(s): Nomura; Sumihiro & Kawanishi; Eiji & Ueta; Kiichiro
    Assignee(s): Mitsubishi Tanabe Pharma Corporation
    A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Patent expiration dates:
    • July 14, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Glucopyranoside compound
    Patent 8,222,219
    Issued: July 17, 2012
    Inventor(s): Nomura; Sumihiro & Kawanishi; Eiji & Ueta; Kiichiro
    Assignee(s): Mitsubishi Tanabe Pharma Corporation
    A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.
    Patent expiration dates:
    • July 30, 2024
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
  • Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
    Patent 8,513,202
    Issued: August 20, 2013
    Assignee(s): Mitsubishi Tanabe Pharma Corporation
    A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.
    Patent expiration dates:
    • December 3, 2027
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 29, 2018 - NEW CHEMICAL ENTITY
    • May 20, 2019 - USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide